The effects of c-Src kinase on EMT signaling pathway in human lens epithelial cells associated with lens diseases

CURRENT STATUS: ACCEPTED

BMC Ophthalmology  |  BMC Series

Xing-Yu Li
Xijing Hospital, Fourth Military Medical University

Fang Wang
Xijing Hospital, Fourth Military Medical University

Mei-Xia Ren
Xijing Hospital, Fourth Military Medical University

Min-Juan Du
Xijing Hospital, Fourth Military Medical University

Jian Zhou
Xijing Hospital, Fourth Military Medical University

zhoujian@fmmu.edu.cn  Corresponding Author

DOI:
10.21203/rs.2.9375/v3

SUBJECT AREAS
Internal Medicine Specialties

KEYWORDS
c-Src kinase, lens epithelial cells, epithelial to mesenchymal transition, cataract, fibrosis
Abstract

Background: The signaling pathway of epithelial to mesenchymal transition (EMT) is regulated by c-Src kinase in many cells. The purpose of this study was to investigate the effects of c-Src kinase on EMT of human lens epithelial cells in vivo stimulated by different factors. Methods: Human lens epithelial cells, HLE-B3, were exposed to either an inflammatory factor, specifically IL-1α, IL-6, TNF-α or IL-1β, at 10 ng/mL or high glucose (35.5 mM) for 30 mins. Activity of c-Src kinase was evaluated by the expression of p-Src 418 with western blot assay. To investigate the effects of activation of c-Src on EMT, HLE-B3 cells were transfected with pCDNA3.1-Src Y530F to upregulate activity of c-Src kinase, and pSilence4.1-ShSrc to knock it down. The expressions of c-Src kinase and molecular markers of EMT such as E-cadherin, ZO-1, α-SMA, and vimentin were examined at 48 hours by RT-PCR and western blot. At 48 hours and 72 hours of transfection, cell proliferation was detected by MTT, and cell mobility and migration were determined by scratch and transwell assay. Results: Activity of c-Src kinase, which causes the expression of p-Src 418, was upregulated by different inflammatory factors and high glucose in HLE-B3 cells. When HLE-B3 cells were transfected with pCDNA3.1-Src Y530F, the expression of c-Src kinase was upregulated on both mRNA and protein levels, and activity of c-Src kinase, expression of p-Src 418 increased. The expression of both E-cadherin and ZO-1 was suppressed, while the expressions of vimentin and α-SMA were elevated on both mRNA and protein levels at the same time. Cell proliferation, mobility and migration increased along with activation of c-Src kinase. Conversely, when HLE-B3 cells were transfected with pSilence4.1-ShSrc, both c-Src kinase and p-Src 418 expression were knocked down. The expression of E-cadherin and ZO-1 increased, but the expression of vimentin and α-SMA decreased; meanwhile, cell proliferation, mobility and migration reduced. Conclusions: The c-Src kinase in lens epithelial cells is easily activated by external stimuli, resulting in the induction of cell proliferation, mobility, migration and EMT.

Background

Previous studies have shown that lens fibrotic disorders, such as anterior subcapsular cataract (ASC) and posterior capsular opacification (PCO), are common types of cataract and visual impairment. ASC is a primary cataract, which is characterized by dense fibrotic regions underneath the anterior capsule.
and is mainly caused by inflammation, ocular trauma and irritation [1]. PCO, a secondary cataract, occurs in 30% to 50% of adults and almost 100% of children who receive cataract surgery [2], and it is associated with fibrosis and contraction of the posterior lens capsule [2-4]. ASC and PCO share many molecular features such as aberrant proliferation, migration and epithelial to mesenchymal transition (EMT) of lens epithelial cells (LECs) [5]. Accumulating evidence shows that anti-inflammatory treatments after cataract surgery could reduce migration and fibrosis of LECs [6-8]. It has been reported that fibrosis of LECs in patients with diabetes mellitus was significantly higher than in patients without diabetes at 6 and 12 months after cataract extraction [9]. These studies suggest that inflammatory factors and high glucose are the stimulating factors for fibrosis of LECs.

EMT is associated with many molecular and morphologic changes to epithelial cells that enable them to lose their cell polarity and cell-cell adhesion, gain properties in migration and invasion and become mesenchymal cells [10, 11]. The most marked characteristics of EMT are loss of epithelial markers, such as E-cadherin and ZO-1, and acquisition of a spindle shape cell, which is accompanied by accumulation of Vimentin and a-smooth muscle actin (a-SMA) [12]. This specific process is present in embryonic development, wound healing and tissue repairment and tumor metastasis. In organ fibrosis such as renal fibrosis, pulmonary fibrosis, hepatic fibrosis and ocular fibrosis, EMT is triggered by various biomolecules and signaling pathways, such as transforming growth factor-β (TGF-β) [13], insulin-like growth factor-1 (IGF-1) [14], transcription factor snail [15], and PI3K/Akt/mTOR/NF-κB signaling [16].

c-Src kinase, one of the Src-family tyrosine kinases (SFKs), is activated by many stimulators, such as epidermal growth factor receptor (EGFR) [17], P2RY2 (a purinergic GPCR receptor) and reactive oxygen species (ROS) [18], high glucose [19], heterotrimeric G protein-coupled receptors [20], PKA signaling [21] and the pathways of IL-1 and EGFR/integrin signaling [22]. Activation of c-Src kinase is required for cell differentiation, migration and change of intercellular junction, including cadherin-based intercellular adhesions and integrin-mediated cell-matrix adhesions of epithelial cells, particularly during EMT [23, 24]. Inhibition of SFKs with their specific inhibitors attenuates fibrosis in lung, pancreas and skin, which suggests that activation of Src kinase is an attractive trigger point of
organ fibrosis [25, 26]. In lens epithelial cells, activation of Src kinase induced by serum increased cell migration, weakened cell-cell junctions, and caused lens epithelial cells to acquire the phenotype of mesenchymal cells [27].

The c-Src kinase is made up of a lipophilic N-terminus, followed by the regulatory SH3 and SH2 domains, a catalytic protein tyrosine kinase (PTK) core, and a c-terminus regulatory tail [28-30]. The PTK domain contains the kinase domain and a conserved tyrosine residue involved in autophosphorylation. Phosphorylation of the Tyr 418 residue of the PTK domain is required for maximum kinase activity [31]. A negative regulatory domain is adjacent to the PTK domain. Phosphorylated Tyr 530 interacts and binds with the SH2 domain to keep the SFK in the inactive conformation. In other words, c-Src kinase is activated by phosphorylation at Tyr 418 or dephosphorylation at Tyr 530 [32].

In the present study, we hypothesized that activation of c-Src kinase stimulated by a variety of factors, such as inflammatory factors or high glucose, could be a trigger for EMT of LECs. By transfecting HLE-B3 cells with c-Src activated vector or ShRNA vector, the effects of c-Src kinase on cell proliferation, mobility, migration and EMT were observed.

Methods

Plasmid construction

Construction of pCDNA3.1-c-Src<sup>Y530F</sup> recombination vector was described previously [33-35]. Mutant c-Src<sup>Y530F</sup> cDNA generated by RT-PCR from total mRNA of HLE-B3 cells with the primers:

- sense 5'-GGCAAGCTTATGGGTAGCAACAAGAGCAAGCCCAAG-3';
- antisense 5'-GCTCTAGACTAGAGGTTCTCCCCGGAGCGAACACTG-3' (underlined sequences was the mutation site) was cloned into the expression vector pCDNA3.1 (Invitrogen, Carlsbad, CA, USA), creating pCDNA3.1-c-Src<sup>Y530F</sup> recombination vector. ShRNA expression vectors were generated by annealing single-stranded oligonucleotides and inserting them into the BamHI and HindIII enzyme sites of pSilencer4.1-CMVneo vector (Ambion, Austin, TX, USA). The target sequences were as follows: ShSrc (c-Src, NM_005417, 1682-1700 bp): 5'-TCGGCTCATTGAAGATAT-3' (provided by Genepharma Inc, Shanghai, China), and a scrambled
sequence was used as a negative control (ShNC): 5′-TTCTCCGAACGTGTCACGT-3′ (Ambion, Austin, TX, USA). The recombinant ShRNA vectors were named as pSilence4.1-ShSrc and pSilence4.1-ShNC.

**Cell culture**

Human lens epithelial cells, HLE-B3 cells were grown adherently in Dulbecco's modified Eagle's medium (DMEM, with 5.5 mM glucose) with 10% fetal bovine serum and 2 mM L-glutamine, and incubated at 37°C with 5% CO₂ [19]. All cells used in the experiments were taken in logarithmic phase.

**Groups and treatment**

Groups of stimulation with inflammatory factors: in the treatment groups, HLE-B3 cells were treated with IL-1α, IL-6, TNF-α, or IL-1β at 10 ng/mL for 30 mins. In the control group, HLE-B3 cells were cultured in DMEM with 0.5% fetal bovine serum for 30 mins.

Groups of stimulation with high glucose: in the control group (5.5 mM), HLE-B3 cells were cultured in DMEM with 5.5 mM glucose in the medium for 30 mins; in the osmotic control group (mannitol), the cultured cells were treated with 30 mM mannitol for 30 mins; and in the high glucose group (35.5 mM), the cells were treated with 30 mM glucose for 30 mins.

Groups of c-Src kinase activation: in the c-Src activation group (pCDNA3.1-c-Src<sup>Y530F</sup>), HLE-B3 cells were transfected with pCDNA3.1-c-Src<sup>Y530F</sup> recombination vector. In the blank control group (pCDNA3.1), cells were transfected with blank vector, pCDNA3.1 vector. In the negative control group (control), cells were transfected with transfection reagent Lipofectamine 2000.

Groups of c-Src kinase inhibition: in the c-Src silence group (ShSrc), HLE-B3 cells were transfected with pSilence4.1-ShSrc vector. In the blank control group (ShNC), the cells were transfected with pSilence4.1-ShNC vector, and in the negative control group (control), cells were transfected with transfection reagent Lipofectamine 2000.

**Transfection**

HLE-B3 cells (2×10⁵ cells/well) were seeded in 6-well plates and grown overnight to 80% confluence prior to transfection. All transfections for plasmids were performed with Lipofectamine 2000.
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Plasmid DNA-lipid complexes (4 μg plasmids in 8 μl Lipofectamine 2000 per well) were quickly prepared and then incubated for 20 mins at room temperature. The DNA-lipid complexes were added to HLE-B3 cells in 6-well plates and were cultured for 4–6 hours. Lastly, DNA-lipid complexes were discarded, and 2 ml complete medium were added. Finally, 400 μg G418 (Invitrogen, Carlsbad, CA, USA) was applied to select neomycin-resistant cells.

**Quantitative real-time PCR (RT-PCR)**

Total RNA was extracted from cells using Trizol reagent (Takara, Dalian, China), and 1 μg total RNA was used as the template for cDNA synthesis in a reverse transcription kit (Takara, Dalian, China). RT-PCR was performed in the SYBR Green kit (Takara, Dalian, China) using specific primers for c-Src, E-cadherin, ZO-1, vimentin and αSMA (Table 1). The relative expression levels of genes were normalized to the endogenous housekeeping gene GAPDH.

**Table 1 Primers for quantitative real-time PCR**

| Gene    | GenBank ID | Primer pairs (5'→3')                                                                 |
|---------|------------|--------------------------------------------------------------------------------------|
| c-Src   | NM_005417  | F:AAGCCTGGCACGATGTCT                                                                |
|         |            | R:CGATGTAATGGGCTCTCT                                                                |
| E-Cadherin | AB025106 | F:CCCCGCCCTATGATTCTCT                                                                |
|         |            | R: GCCCCATCGTTCAAGTA                                                                |
| ZO-1    | NM_003257  | F: CTGCTTGACCTCCTAAA                                                                 |
|         |            | R: ATCCACAACACGGACAC                                                                 |
| Vimentin | NM_003380 | F: AGCTCCAGCCGGAGCTAC                                                                |
|         |            | R: CGCTGCTCCGCCAGGGCGCA                                                              |
| αSMA    | NM_001141945 | F: TGCTCCAGGGCTGTTTT                                                              |
|         |            | R: GCCATGTTCTATCGGGGTACCTTC                                                          |
| GAPDH   | NG 007073.2 | F: CCACATCGCTCAGACACCAT                                                            |
|         |            | R: GGCAACAAATATCCACTTTACCAGAGT                                                      |

**Western blot**

Cells were harvested and lysed in RIRA cell lysate (50 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS and 0.5 mM PMSF) (Beyotime Biotechnology, Beijing, China), and total proteins were extracted. The proteins were quantified by BCA assay kit (Beyotime Biotechnology, Beijing, China), and 5×loading buffer (250 mM Tris-HCl (pH 6.8), 10% SDS, 0.5% BPB, 50% Glycerin, 5% 2-Mercaptoethanol) was added to the proteins. Next, 35 μg total proteins from each
sample were uploaded and separated in 12% SDS-PAGE at 120 V voltage, then transferred onto PVDF membranes at 40 mA for 2.5 hours at room temperature. According to the standard protein marker, the PVDF membrane was cut according to the molecular weight of the target protein. After blocking by 5% defatted milk powder for two hours at room temperature, PVDF membrane bands were incubated with primary antibodies overnight at 4°C, such as, c-Src (1:1000, ab109381, Abcam, Cambridge, UK), p-Src\textsuperscript{418} (1:500, ab133460, Abcam, Cambridge, UK), E-Cadherin (1:200, #3195, Cell Signal Technology, Danvers, MA, USA), ZO-1 (1:1000, 21773-1-AP, Proteintech, Chicago, IL, USA), Vimentin (1:1000, ab92547, Abcam, Cambridge, UK), α-SMA (1:1000, ab124964, Abcam, Cambridge, UK) and GAPDH (1:2000, Cell Signal Technology, Danvers, MA, USA). After being washed with TBST three times (for 15 mins each) the next day, PVDF membrane bands were incubated with secondary antibodies (1:4000, Cell Signal Technology, Danvers, MA, USA) for four hours at 4°C. After being washed with TBST, proteins in PVDF membrane bands were detected with luminol reagent (Santa Cruz, USA). GAPDH expression was used as the internal standard. The protein bands were observed and captured with a scanner (HP Deskjet F2288, China). The images were analyzed by Quantity One software.

**Cell proliferation assay**

Cell proliferation was evaluated by MTT (Sigma, St Louis, MO, USA) assay at indicated time points [36]. HLE-B3 cells (2×10\textsuperscript{5} cells/well) were seeded in 6-well plates. The next day, cells were transfected with pCDNA3.1-c-Src\textsuperscript{Y530F}, pSilence4.1-ShSrc and control vectors. After transfection for 24 hours, cells in activation of c-Src kinase group, inhibition of c-Src kinase group and control group were trypsinized and seeded in 96-well plates (6×10\textsuperscript{3} cells/well). At different time points (after sticking for 0, 12, 24, 48 and 72 hours), the medium was replaced with 100 μl MTT (5 mg/ml), and the plate was incubated at 37°C for another 4 hours. After incubation, the culture medium was removed gently, and 100 μl DMSO was added. Finally, the absorbance was determined on a microreader (Bio-Rad, Hercules\textsuperscript{□}CA\textsuperscript{□}USA) at 570 nm. All experiments were performed three times independently. The cell proliferation diagram was plotted using the absorbance at each time point.
**Scratch assay**

HLE-B3 cells (2×10⁵ cells/well) were seeded in 6-well plates. On the second day, cells were transfected with pCDNA3.1-c-Src⁵³⁰F, pSilence4.1-ShSrc and control vectors. After 24 hours, cells in each well were scratched with a 200 μl pipette tip. Once scratches were made, the plates were gently washed with PBS three times, and then 2 ml serum-free medium was added. Cell mobility was examined after 24 hours and 48 hours. The images at 0 hours (T0), which was just after scratching, 24 hours (T24) and 48 hours (T48) were taken with a digital camera (Olympus DP71, Japan) connected to an inverted microscope (Olympus IX71, Japan). Ten fields of each plate were picked randomly and marked. Measurements of the width of gap were repeated three times at the same field. Gap closure (%) = [Gap in width (T0- T24/48)/Gap in width T0] × 100%.

**Transwell assay**

Cell migration was determined using transwell assay (Corning incorporated, NY, USA). HLE-B3 cells (2×10⁵ cells/well) were seeded in 6-well plates. On the following day, cells were transfected with pCDNA3.1-c-Src⁵³⁰F, pSilence4.1-ShSrc vector and control vectors. After transfection for 24 hours, cells in each group were trypsinized and seeded in matrigel coated filters (2x10⁴ cells/well) and cultured with 100 μl serum-free medium. Then 600 μl completed medium was added into the lower compartment of chamber. After incubation for 24 hours and 48 hours, cells on the upper surface of the filter were wiped off with a swab, whereas cells that had passed through the filter were fixed with 95% ethanol, stained with crystal violet and counted under the microscope. Relative migration was based on the average number of cells on the underside of the membrane in ten random images generated at 4× magnification under the microscope.

**Data analysis and statistics**

Each experiment was repeated three times independently, and all results were presented as mean ± standard deviation (SD). All data were analyzed using SPSS 19.0 software. Multiple-group comparison was performed by analysis of variance (ANOVA), followed by LSD test for between-group comparison. Values of P < 0.05 were considered as significant and indicated by asterisks in the figures.
Results

Inflammatory factors and high glucose activated c-Src kinase

Using western blot assay, we found that after treatment with inflammatory factors IL-1α, IL-6, TNF-α and IL-1β for 30 mins, the activity of c-Src kinase (gray ratio of p-Src\textsuperscript{418}/c-Src) in HLE-B3 cells was enhanced significantly compared with the control group. The effect of TNF-α on activation of c-Src kinase was the strongest (Fig. 1A). The expression of p-Src\textsuperscript{418} in the 35.5 mM glucose group was significantly higher than that in the 5.5-mM glucose group and mannitol group, whereas that in the mannitol group was almost the same as in the 5.5-mM glucose group (Fig. 1B). These results suggested that both inflammatory factors and high glucose stimulated the activity of c-Src kinase in HLE-B3 cells.

Alteration of c-Src kinase activity in HLE-B3 transfected with pCDNA3.1-c-Src\textsuperscript{Y530F} vector or pSlience4.1-ShSrc vector

First, pCDNA3.1-c-Src\textsuperscript{Y530F} and pSlience4.1-ShSrc vectors were constructed and transfected into HLE-B3 cells for 48 hours. To evaluate the activating and inhibitive effects on c-Src kinase, RT-PCR and western blot assay were applied to examine the expressions of c-Src kinase on mRNA and protein levels, respectively. In HLE-B3 cells transfected with pCDNA3.1-c-Src\textsuperscript{Y530F} (group pCDNA3.1-c-Src\textsuperscript{Y530F}), the expressions of c-Src mRNA and protein were significantly higher than two control groups (group pCDNA3.1 and group control). Furthermore, activity of c-Src kinase, the expression of p-Src\textsuperscript{418}, was much higher than controls (Fig. 2A&B), suggesting that c-Src kinase was activated by pCDNA3.1-Src\textsuperscript{Y530F} vectors in the cells. In HLE-B3 cells transfected with pSlience4.1-ShSrc vector (group ShSrc), obvious suppressions of c-Src in mRNA and protein levels were demonstrated, and p-Src\textsuperscript{418} protein expression was also decreased (Fig. 2C&D), implying that expression of endogenous c-Src was suppressed by ShRNA.

Activation of c-Src kinase promoted EMT of HLE-B3 cells

To explore the biological roles of activation of c-Src kinase on EMT of LECs, we further examined the expression of epithelial cell proteins such as E-cadherin and ZO-1, and the mesenchymal cell proteins
such as vimentin and αSMA in cells of group pCDNA3.1-c-Src$^{Y530F}$, in which c-Src kinase was activated. It was shown by RT-PCR and western blot that the expression of both E-cadherin and ZO-1 reduced significantly, and vimentin and αSMA increased dramatically compared with cells in control groups (group pCDNA3.1 and group control) (Fig. 3A&B). In pSilence4.1-ShSrc vector transfected cells, in which c-Src was knocked down, the expressions of E-cadherin and ZO-1 increased, while vimentin and αSMA reduced significantly compared with control cells (group ShNC and group control) (Fig. 3C&D). Altogether, activation of c-Src kinase could induce EMT process in HLE-B3 cells.

**Activation of c-Src kinase stimulated cell proliferation**

MTT assay showed that proliferation of cells in group pCDNA3.1-c-Src$^{Y530F}$ increased by 9%, 9%, 25% and 39% compared with that in group pCDNA3.1 at 12 hours, 24 hours, 48 hours and 72 hours, respectively. The proliferation of cells in group pCDNA3.1- c-Src$^{Y530F}$ increased by 4%, 9%, 21% and 37% compared with that in the control group at 12 hours, 24 hours, 48 hours and 72 hours, respectively (Fig. 4A), while in cells of group ShSrc, the proliferation did not change at 12 hours compared with two control groups, but reduced by 2%, 7% and 13% compared to group ShNC, and 3%, 8% and 14% compared to control group at 24 hours, 48 hours and 72 hours, respectively (Fig. 4B). This indicated that activation of c-Src kinase stimulated cell proliferation.

**Activation of c-Src kinase increased cell mobility and migration**

By scratch assay, gap closure in cells of group pCDNA3.1- c-Src$^{Y530F}$ increased by 84%, 60% compared with group pCDNA3.1 and 137%, 65% compared with the control group at 24 hours and 48 hours, respectively, which suggested the enhancing of migration ability after activation of c-Src kinase in HLE-B3 cells (Fig. 5A), while in HLE-B3 cells transfected with pSilence4.1-ShSrc vector (group ShRNA), gap closure was reduced by 63%, 62% compared with group ShNC and 65%, 65% compared with control group at 24 hours and 48 hours, respectively (Fig. 5B).

In transwell assay, the migrating cell number in group pCDNA3.1- c-Src$^{Y530F}$ increased by 71%, 152.8% compared with group pCDNA3.1, and 83.9%, 177.9% compared with the control group at 24 hours and 48 hours, respectively (Fig. 6A). In contrast, in cells of group ShSrc, this number was
reduced by 31.5%, 41.6% compared to group ShNC, and 29.6%, 40.3% compared with control group at 24 hours and 48 hours, respectively (Fig. 6B). This suggested that activation of c-Src could induce cell mobility and migration.

Discussion
EMT is a conserved and essential process shared by developmental morphogenesis and carcinogenesis as well as physiological response to injury, operations and tissue fibrotic diseases. In lens fibrotic diseases, EMT is an important pathological process; for instance, in ASC and PCO. Our present study showed that inflammatory factors and high glucose stimulated the activity of c-Src kinase in HLE-B3 cells, and activation of c-Src kinase promoted the EMT process, cell migration and cell proliferation in HLE-B3 cells. In contrast, when c-Src kinase was inhibited, the EMT process and cell migration and proliferation were reduced. All of these data suggested that c-Src is a key regulator in the lens diseases associated with EMT.

Activation of c-Src kinase could promote the EMT process as well as cell migration and proliferation in HLE-B3 cells, which is consistent with the role of c-Src kinase in tumors. Activation of c-Src kinase affects the EMT process and enhances cell migration and proliferation in many cancer cells [37, 38]. In various types of cancer, such as breast cancer, pancreatic cancer and castration-resistant prostate cancer, activation of c-Src increases cell invasiveness by altering the activity of cadherins, adhesion proteins and integrins[39].

Src activation stimulates downstream kinases such as extracellular signal-regulated kinase (ERK) [40] and GSK3 [41, 42], which are involved in the regulation of cell survival and proliferation and the promotion of EMT. The interaction of activated Src with p120-catenin may cause dissociation of cell-cell junctions, thus facilitating cell mobility [43]. Similarly, LECs in the EMT process experience a loss of cell adhesion from epithelial cells and gain the ability of proliferation and migration as they transition into mesenchymal cells [44]. In fibroblasts, the binding of integrins to their ligands leads to activation of focal adhesion plaques adhesion kinase (FAK), which, in turn, recruits and activates c-Src [45]. Furthermore, activation of c-Src is required to disrupt cadherin-dependent cell-cell contact [46]. Our results showed that activation of c-Src reduced the expression of E-cadherin at the protein and
mRNA levels in HLE-B3 cells. This may be one of the mechanisms by which activation of c-Src induces EMT of lens epithelial cells. E-cadherin is the major cadherin molecule expressed in epithelial cells and is down-regulated in mesenchymal cells [47]. Loss of E-cadherin is the characteristic associated with the increasing potential to invade surrounding tissues and disseminate to distant sites, and it is the hallmark of EMT [48-50]. E-cadherin is a single-span transmembrane glycoprotein that maintains intercellular contacts and cellular polarity in epithelial tissues. In tumor cells, loss of E-cadherin is associated with cell invasion and metastasis [51]. In pancreatic ductal adenocarcinoma (PDAC) cell lines, overexpression of activated c-Src induces down-regulation of E-cadherin [52]. When c-Src binds to E-cadherin, it disrupts cell-cell interaction, enabling cancer cells to detach from their original site [53]. These results from previous studies supported our findings that activation of c-Src kinase increased cell motility and induced EMT.

It is known that TGF-β plays a key role in EMT of epithelial cells through TGF-β/Smad [54, 55] and TGF-β/HIF-1α signaling pathways [56]. Our previous study suggested that c-Src kinase regulated EMT of LECs through TGF-β signaling pathway, based on the evidence that following the inhibition of c-Src kinase in LECs stimulated by high glucose, the expression of TGF-β and its receptor ALK5 decreased significantly, and EMT of HLE-B3 cells was prevented [19].

Conclusions
The results of this study indicated that c-Src kinase could be activated by inflammatory factors and high glucose. Activation of c-Src kinase elevated EMT and cell proliferation, mobility and migration of LECs, whereas silencing the c-Src gene in HLE-B3 led to the opposite effects. Activation of c-Src was a trigger for EMT of lens epithelial cells associated with fibrosis of lens diseases.

Abbreviations
ASC: anterior subcapsular cataract; DMEM: Dulbecco’s modified Eagle’s medium; EGFR: epidermal growth factor receptor; EMT: epithelial-mesenchymal transition; ERK: extracellular signal-regulated kinase; FAK: focal adhesion plaques adhesion kinase; IGF-1: insulin-like grow factor-1; LECs: lens epithelial cells; PCO: posterior capsular opacification; PDAC: pancreatic ductal adenocarcinoma; PTK: protein tyrosine kinase; ROS: reactive oxygen species; SFKs: Src family kinases; a-SMA: a-smooth
muscle actin; TGF-β: transforming growth factor-β.

Declarations

Acknowledgment

HLE-B3 cells were kindly provided by Dr. Wei Zhang (Beijing Tongren Eye Center, China). We thank LetPub (www.letpub.com) for its linguistic assistance during the preparation of this manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (No.81370998), the New Century Excellent Talents Program of China (NCET-06-932), and the Innovation Science and Technology Project of Shaanxi Province (No.2012KTCQ03-03).

Availability of data and materials

All data generated or analyzed during this study are included in this published article. More details are available from the corresponding author on reasonable request.

Authors' contributions

Conceived and designed the experiments: J. Z.

Performed the experiments: X-Y. L., M-X. R., M-J. D.

Analyzed the data: X-Y. L., F.W., J. Z.

Wrote the paper: X-Y. L., J. Z.

All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

References

1. Eldred JA, Dawes LJ, Wormstone IM. The lens as a model for fibrotic disease. Philos Trans R Soc Lond B Biol Sci. 2011;366(1568):1301-1319.
2. Awasthi N, Guo S, Wagner BJ. Posterior capsular opacification: a problem reduced but not yet eradicated. Arch Ophthalmol. 2009;127(4):555-562. http://doi.org/10.1001/archophthalmol.2009.3.

3. Raj SM, Vasavada AR, Kaid Johar SR, Vasavada VA, Vasavada VA. Post-operative capsular opacification: a review. Int J Biomed Sci. 2007;3(4):237-250.

4. Moreno-Montanes J, Alvarez A, Maldonado MJ. Objective quantification of posterior capsule opacification after cataract surgery, with optical coherence tomography. Invest Ophthalmol Vis Sci. 2005;46(11):3999-4006. http://doi.org/10.1167/iovs.04-1531.

5. Su Y, Wang F, Yan Q, Teng Y, Cui H. Inhibition of proliferation of rabbit lens epithelial cells by S-phase kinase-interacting protein 2 targeting small interfering RNA. Mol Vis. 2010;16:907-915.

6. Jiang A, shihan MH, Wang Y, Duncan MK. Lens Epithelial Cells Initiate an Inflammatory Response Following Cataract Surgery. Invest Ophthalmol Vis Sci. 2018;59(12):4986-4997. http://doi.org/10.1167/iovs.18-25067.

7. Cortina P, Gomez-Lechon MJ, Navea A, Menezo JL, Terencio MC, Diaz-Llopis M. Diclofenac sodium and cyclosporin A inhibit human lens epithelial cell proliferation in culture. Graefes Arch Clin Exp Ophthalmol. 1997;235(3):180-185.

8. Nishi O, Nishi K, Fujiwara T, Shirasawa E. Effects of diclofenac sodium and indomethacin on proliferation and collagen synthesis of lens epithelial cells in vitro. J Cataract Refract Surg. 1995;21(4):461-465.

9. Ebihara Y, Kato S, Oshika T, Yoshizaki M, Sugita G. Posterior capsule opacification after cataract surgery in patients with diabetes mellitus. J Cataract Refract Surg. 2006;32(7):1184-1187. http://doi.org/10.1016/j.jcrs.2006.01.100.
10. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13(2):97-110. http://doi.org/10.1038/nrc3447.

11. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420-1428. http://doi.org/10.1172/JCI39104.

12. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009;119(6):1429-1437. http://doi.org/10.1172/JCI36183.

13. Lu L, Zhu J, Zhang Y, Wang Y, Zhang S, Xia A. Febuxostat inhibits TGFbeta1-induced epithelial-mesenchymal transition via downregulation of USAG1 expression in MadinDarby canine kidney cells in vitro. Mol Med Rep. 2019;19(3):1694-1704. http://doi.org/10.3892/mmr.2019.9806.

14. Graham TR, Zhau HE, Odero-Marah VA, Osunkoya AO, Kimbro KS, Tighiouart M, et al. Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res. 2008;68(7):2479-2488. http://doi.org/10.1158/0008-5472.CAN-07-2559.

15. Brzozowa M, Michalski M, Wyrobiec G, Piecuch A, Dittfeld A, Harabin-Slowinska M, et al. The role of Snail1 transcription factor in colorectal cancer progression and metastasis. Contemp Oncol (Pozn). 2015;19(4):265-270. http://doi.org/10.5114/wo.2014.42173.

16. Ahmad A, Biersack B, Li Y, Kong D, Bao B, Schobert R, et al. Targeted regulation of PI3K/Akt/mTOR/NF-kappaB signaling by indole compounds and their derivatives: mechanistic details and biological implications for cancer therapy. Anticancer Agents Med Chem. 2013;13(7):1002-1013.

17. Singh S, Trevino J, Bora-Singhal N, Coppola D, Haura E, Altik S, et al. EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol Cancer. 2012;11:73-87. http://doi.org/
18. Giannoni E, Chiarugi P. Redox circuitries driving Src regulation. Antioxid Redox Signal. 2014;20(13):2011-2025. http://doi.org/10.1089/ars.2013.5525.

19. Han ZH, Wang F, Wang FL, Liu Q, Zhou J. Regulation of transforming growth factor beta-mediated epithelial-mesenchymal transition of lens epithelial cells by c-Src kinase under high glucose conditions. Exp Ther Med. 2018;16(2):1520-1528. http://doi.org/10.3892/etm.2018.6348.

20. Malarkey K, Belham CM, Paul A, Graham A, McLees A, Scott PH, et al. The regulation of tyrosine kinase signalling pathways by growth factor and G-protein-coupled receptors. Biochem J. 1995;309 (Pt 2):361-375.

21. Beristain AG, Molyneux SD, Joshi PA, Pomroy NC, Di Grappa MA, Chang MC, et al. PKA signaling drives mammary tumorigenesis through Src. Oncogene. 2015;34(9):1160-1173. http://doi.org/10.1038/onc.2014.41.

22. Bjorge JD, Jakymiw A, Fujita DJ. Selected glimpses into the activation and function of Src kinase. Oncogene. 2000;19(49):5620-5635.

23. Avizienyte E, Frame MC. Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition. Curr Opin Cell Biol. 2005;17(5):542-547. http://doi.org/ 10.1016/j.ceb.2005.08.007.

24. Avizienyte E, Fincham VJ, Brunton VG, Frame MC. Src SH3/2 domain-mediated peripheral accumulation of Src and phospho-myosin is linked to deregulation of E-cadherin and the epithelial-mesenchymal transition. Mol Biol Cell. 2004;15(6):2794-2803. http://doi.org/10.1091/mbc.e03-12-0879.

25. Hu M, Che P, Han X, Cai GQ, Liu G, Antony V, et al. Therapeutic targeting of SRC kinase in myofibroblast differentiation and pulmonary fibrosis. J Pharmacol Exp Ther. 2014;351(1):87-95. http://doi.org/10.1124/jpet.114.216044.
26. Skhirtladze C, Distler O, Dees C, Akhmetshina A, Busch N, Venalis P, et al. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum. 2008;58(5):1475-1484. http://doi.org/10.1002/art.23436.

27. Zhou J, Leonard M, Van Bockstaele E, Menko AS. Mechanism of Src kinase induction of cortical cataract following exposure to stress: destabilization of cell-cell junctions. Mol Vis. 2007;13:1298-1310.

28. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 2003;22(4):337-358.

29. Kopetz S, Shah AN, Gallick GE. Src continues aging: current and future clinical directions. Clin Cancer Res. 2007;13(24):7232-7236. http://doi.org/10.1158/1078-0432.CCR-07-1902.

30. Boggon TJ, Eck MJ. Structure and regulation of Src family kinases. Oncogene. 2004;23(48):7918-7927. http://doi.org/10.1038/sj.onc.1208081.

31. Williams JC, Wierenga RK, Saraste M. Insights into Src kinase functions: structural comparisons. Trends Biochem Sci. 1998;23(5):179-184.

32. Schlessinger J. New roles for Src kinases in control of cell survival and angiogenesis. Cell. 2000;100(3):293-296.

33. Kmiecik TE, Shalloway D. Activation and suppression of pp60c-src transforming ability by mutation of its primary sites of tyrosine phosphorylation. Cell. 1987;49(1):65-73.

34. Cooper JA, Gould KL, Cartwright CA, Hunter T. Tyr527 is phosphorylated in pp60c-src: implications for regulation. Science. 1986;231(4744):1431-1434.

35. Boerner RJ, Kassel DB, Barker SC, Ellis B, DeLacy P, Knight WB. Correlation of the phosphorylation states of pp60c-src with tyrosine kinase activity: the intramolecular pY530-SH2 complex retains significant activity if Y419 is phosphorylated.
36. Chen X, Shen J, Li X, Wang X, Long M, Lin F, et al. Rlim, an E3 ubiquitin ligase, influences the stability of Stathmin protein in human osteosarcoma cells. Cell Signal. 2014;26(7):1532-1538. http://doi.org/10.1016/j.cellsig.2014.03.018.

37. Patel A, Sabbineni H, Clarke A, Somanath PR. Novel roles of Src in cancer cell epithelial-to-mesenchymal transition, vascular permeability, microinvasion and metastasis. Life Sci. 2016;157:52-61. http://doi.org/10.1016/j.lfs.2016.05.036.

38. Bartscht T, Rosien B, Rades D, Kaufmann R, Biersack H, Lehnerta H, et al. Inhibition of TGF-beta Signaling in Tumor Cells by Small Molecule Src Family Kinase Inhibitors. Anticancer Agents Med Chem. 2017;17(10):1351-1356. http://doi.org/10.2174//18715206176661 70103094946.

39. Hamaguchi M, Matsuyoshi N, Ohnishi Y, Gotoh B, Takeichi M, Nagai Y. p60v-src causes tyrosine phosphorylation and inactivation of the N-cadherin-catenin cell adhesion system. Embo J. 1993;12(1): 307-314.

40. Zhang S, Yu D. Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. Trends Pharmacol Sci. 2012;33(3):122-128. http://doi.org/10.1016/j.tips.2011.11.002.

41. Gao F, Al-Azayzih A, Somanath PR. Discrete functions of GSK3alpha and GSK3beta isoforms in prostate tumor growth and micrometastasis. Oncotarget. 2015;6(8):5947-5962. http://doi.org/ doi:10. 18632/ oncotarget.3335.

42. Goc A, Al-Husein B, Katsanevas K, Steinbach A, Lou U, Sabbineni H, et al. Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression in vitro and in vivo. Oncotarget. 2014;5(3):775-787. http://doi.org/10. 18632/ oncotarget.1770.

43. Reynolds AB, Rocznia-Ferguson A. Emerging roles for p120-catenin in cell adhesion
and cancer. Oncogene. 2004;23(48):7947-7956.

http://doi.org/10.1038/sj.onc.1208161.

44. Wu X, Ruan J, Ma B, Luo M. Bit1-a potential positive regulator of epithelial-
mesenchymal transition in lens epithelial cells. Graefes Arch Clin Exp Ophthalmol.
2016;254(7):1311-1318. http://doi.org/10.1007/s00417-016-3357-3.

45. Matsuoka H, Nada S, Okada M. Mechanism of Csk-mediated down-regulation of Src
family tyrosine kinases in epidermal growth factor signaling. J Biol Chem.
2004;279(7):5975-5983. http://doi.org/10.1074/jbc.M311278200.

46. Owens DW, McLean GW, Wyke AW, Paraskeva C, Parkinson EK, Frame MC, et al. The
catalytic activity of the Src family kinases is required to disrupt cadherin-dependent
cell-cell contacts. Mol Biol Cell. 2000;11(1):51-64.

http://doi.org/10.1091/mbc.11.1.51.

47. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science.
1991;251(5000):1451-1455.

48. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal
transitions. Nat Rev Mol Cell Biol. 2006;7(2):131-142.

http://doi.org/10.1038/nrm1835.

49. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of
development and tumor metastasis. Dev Cell. 2008;14(6):818-829.

http://doi.org/10.1016/j.devcel.2008.05.009.

50. Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and
metastasis. Cell. 2004;118(3):277-279. http://doi.org/10.1016/j.cell.2004.07.011.

51. Christofori G, Semb H. The role of the cell-adhesion molecule E-cadherin as a tumour-
suppressor gene. Trends Biochem Sci. 1999;24(2):73-76.

52. Menke A, Philippi C, Vogelmann R, Seidel B, Lutz MP, Adler G, et al. Down-regulation
of E-cadherin gene expression by collagen type I and type III in pancreatic cancer cell lines. Cancer Res. 2001;61(8):3508-3517.

53. Chen J. Is Src the key to understanding metastasis and developing new treatments for colon cancer? Nat Clin Pract Gastroenterol Hepatol. 2008;5(6):306-307.

54. Saika S, Kono-Saika S, Ohnishi Y, Sato M, Muragaki Y, Ooshima A, et al. Smad3 signaling is required for epithelial-mesenchymal transition of lens epithelium after injury. Am J Pathol. 2004; 164(2): 651-663. doi:10.1016/S0002-9440(10)63153-7.

55. Saika S, Miyamoto T, Ishida I, Shirai K, Ohnishi Y, Ooshima A, et al. TGFbeta-Smad signalling in postoperative human lens epithelial cells. Br J Ophthalmol, 2002. 86(12): p. 1428-33. doi:10.1136/bjo.86.12.1428.

56. Nahomi, R.B. and R.H. Nagaraj, The role of HIF-1alpha in the TGF-beta2-mediated epithelial-to-mesenchymal transition of human lens epithelial cells. J Cell Biochem. 2018; 119(8): 6814-6827.

Figures
The c-Src kinase was activated by inflammatory factors and high glucose. (A) Left, the expressions of c-Src and p-Src418 (active c-Src kinase) were examined by western blot at 30 mins after treatment with inflammatory factors in HLE-B3 cells. Right, the relative expression of p-Src418, ratio of p-Src418/c-Src. (B) Left, the expressions of c-Src and p-Src418 were examined by western blot in different concentrations of glucose. Right, the relative expression of p-Src418, ratio of p-Src418/c-Src. (**P < 0.01 compared with control, n = 3).
Alterations of c-Src kinase in HLE-B3 transfected with pCDNA3.1-c-SrcY530F vector or pSilence4.1-ShSrc vector. (A) The expressions of mRNA of c-Src kinase examined by RT-PCR in HLE-B3 cells transfected with pCDNA3.1-c-SrcY530F vector (group pCDNA3.1-c-SrcY530F), pCDNA3.1 vector (group pCDNA3.1), and Lipofectamine 2000 (group control) at 48 hours.

(B) Left, the expressions of c-Src kinase examined by western blot at 48 hours after transfection. Right, relative expression of protein in left figure. (*P < 0.05, **P < 0.01 compared with control, #P < 0.05, ##P < 0.01 compared with group pCDNA3.1, n = 3). (C)

The expression of c-Src was examined by RT-PCR in HLE-B3 cells transfected with pSilence4.1-ShSrc vector (group ShSrc), pSilence4.1-ShSrc (group ShNC), and Lipofectamine 2000 (group control) at 48 hours after transfection. (D) Left, the expressions of c-Src kinase (c-Src) and activated c-Src kinase (p-Src 418) examined by western blot at 48 hours after transfection. Right, relative expression of protein in left figure. (*P < 0.05, **P < 0.01 compared with control, #P < 0.05, ##P < 0.01 compared with group ShNC, n = 3).
Figure 3

Effects of c-Src on the expressions of EMT marker proteins in HLE-B3 cells. (A) The expressions of EMT marker proteins were examined by RT-PCR in group pCDNA3.1-c-SrcY530F, group pCDNA3.1 and group control at 48 hours after transfection. (B) Left, the expressions of EMT marker proteins were examined by western blot in group pCDNA3.1-c-SrcY530F, group pCDNA3.1 and group control at 48 hours after transfection. Right, relative expression of protein in left figure. (*P < 0.05, **P < 0.01 compared with control, #P < 0.05, ##P < 0.01 compared with group pCDNA3.1, n = 3). (C) The expression of EMT marker proteins was examined by RT-PCR in group ShSrc, group ShNC and group control at 48 hours after transfection. (D) Left, the expressions of EMT marker proteins were examined by western blot in group ShSrc, group ShNC and group control at 48 hours after transfection. Right, relative expression of protein in left figure. (*P < 0.05, **P < 0.01 compared with control, #P < 0.05, ##P < 0.01 compared with group ShNC, n = 3).
Effect of c-Src on cell proliferation by MTT assay. (A) The effect of c-Src on cell proliferation examined by MTT assay in group pCDNA3.1-c-SrcY530F, group pCDNA3.1 and group control. (*P < 0.05, **P < 0.01 compared with control, #P < 0.05, ##P < 0.01 compared with group pCDNA3.1, n = 3). (B) The effect of c-Src on cell proliferation examined by MTT assay in group ShSsrc, group ShNC and group control. (*P < 0.05, **P < 0.01 compared with control, #P < 0.05, ##P < 0.01 compared with group ShNC, n = 3).
Effect of c-Src on cell migration. (A) The effect of c-Src on cell migration examined by scratch assay in group pCDNA3.1-c-SrcY530F, group pCDNA3.1 and control. (*P < 0.05, **P < 0.01 compared with control, #P < 0.05, ###P < 0.01 compared with group pCDNA3.1, n = 3). (B) The effect of c-Src on cell migration examined by scratch assay in group ShSrc, group ShNC and control. (*P < 0.05, **P < 0.01 compared with control, #P < 0.05, ###P < 0.01 compared with group ShNC, n = 3).
Figure 6

Effect of c-Src on cell mobility. (A) The effect of c-Src on cell mobility examined by transwell assay in group pCDNA3.1-c-SrcY530F, group pCDNA3.1 and control. (*P < 0.05, **P < 0.01 compared with control, #P < 0.05, ###P < 0.01 compared with group pCDNA3.1, n = 3). (B) The effect of c-Src on cell mobility examined by transwell assay in group ShSrc, group ShNC and control. (*P < 0.05, **P < 0.01 compared with control, #P < 0.05, ###P < 0.01 compared with group ShNC, n = 3).

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.
Supplement 1.pdf